As a minimum, there are two main biomarkers of neurodegeneration that are of interest to tau-targeting clinical trial designs for AD, neurofilament light (NfL, measured in plasma or CSF) and magnetic resonance imaging (MRI). The gene discussed is MAPT; the disease is Alzheimer disease.